CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 110 enrolled
Drug / intervention
Imiquimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01861535
NCT01861535Phase 3Completed
CompareCT.gov

Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

Medical University of Graz·interventional·Posted May 23, 2013·Updated Apr 14, 2021

In Brief

A Phase 3 clinical trial evaluating Imiquimod and Surgery for Vulvar Intraepithelial Neoplasia. Completed, enrolled 110 participants across 9 sites.

Detailed Summary

To evaluate the efficacy (defined as complete clinical response at 6 months) of imiquimod vs. standard treatment (surgery) for vulvar intraepithelial neoplasia (VIN).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVulvar Intraepithelial Neoplasia
CountriesAustria
CollaboratorsAustrian Science Fund (FWF)

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 23, 2013
Enrollment StartJun 1, 2013
Primary CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 13.1 years ago

Interventions

Imiquimoddrug

Surgeryprocedure